OccuLogix suspends RHEO programme

Article

OccuLogix has announced that it is indefinitely suspending its RHEO System clinical development programme in dry age-related macular degeneration (AMD).

OccuLogix has announced that it is indefinitely suspending its RHEO System clinical development programme in dry age-related macular degeneration (AMD).

The RHEO procedure is a specific method of apheresis — a treatment in which a patient's blood is drawn outside the body and specific compounds are removed before being returned to the body.

The RHEO procedure uses patented filtering technology to remove excess levels of macro-proteins and fatty components in the blood that have been associated with AMD. These substances, which are known to thicken the blood, decrease blood flow and cause damage to capillary vessels, include LDL cholesterol, fibrinogen and alpha-2-macroglobulin.

The company cited costs and development timelines as its reasons for suspending the programme.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.